AIM ImmunoTech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AIM research report →
About the company
AIM ImmunoTech Inc. , an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts.
- CEO
- Thomas K. Equels
- IPO
- 1995
- Employees
- 21
- HQ
- Ocala, FL, US
Price Chart
- Market Cap
- $952.99K
- P/E
- -0.09
- P/S
- 10.14
- P/B
- 0.57
- EV/EBITDA
- 0.02
- Div Yield
- 0.00%
- Gross Margin
- -132.98%
- Op Margin
- -10839.36%
- Net Margin
- -14123.40%
- ROE
- 261.84%
- ROIC
- -152.10%
- Revenue
- $88.00K · -48.24%
- Net Income
- $-13,958,000 · 19.41%
- EPS
- $-8.62 · 23.20%
- Op Income
- $-10,526,000
- FCF YoY
- 23.96%
- 52W High
- $19.74
- 52W Low
- $0.21
- 50D MA
- $0.43
- 200D MA
- $1.17
- Beta
- 1.17
- Avg Volume
- 27.80M
Get TickerSpark's AI analysis on AIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 26 | Equels Thomas K | other | 25,000 |
| Mar 12, 26 | Equels Thomas K | other | 25 |
| Mar 12, 26 | CHEMEROW DAVID I. | other | 25,000 |
| Mar 12, 26 | CHEMEROW DAVID I. | other | 25 |
| Mar 6, 26 | Equels Thomas K | other | 50,000 |
| Mar 6, 26 | Equels Thomas K | other | 25 |
| Mar 6, 26 | CHEMEROW DAVID I. | other | 50,000 |
| Mar 6, 26 | CHEMEROW DAVID I. | other | 25 |
| Feb 5, 26 | CHEMEROW DAVID I. | other | 2,800 |
| Jul 17, 25 | KELLNER TED D | other | 0 |
Our AIM coverage
Recent articles, reports, and earnings notes.
No research on AIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AIM report →Similar companies
Peers in the same neighborhood.